Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy
Ying Wang(Codagenix (United States)), Chen Yang(Codagenix (United States)), Yutong Song(Codagenix (United States)), J. Robert Coleman(Codagenix (United States)), Marcin Stawowczyk(Codagenix (United States)), Juliana Tafrova(Codagenix (United States)), Sybil Tasker(Codagenix (United States)), David A. Boltz(IIT Research Institute), Robert J. Baker(IIT Research Institute), Liliana Garcia(IIT Research Institute), Olivia Seale(IIT Research Institute), Anna Kushnir(Codagenix (United States)), Eckard Wimmer(Stony Brook University), Steffen Mueller(Codagenix (United States))
Cited by 145Open Access
Abstract
) vaccinated intranasally with COVI-VAC compared to those inoculated with wild-type (WT) virus. COVI-VAC inoculation generated spike IgG antibody levels and plaque reduction neutralization titers similar to those in hamsters inoculated with WT virus. Upon challenge with WT virus, COVI-VAC vaccination reduced lung challenge viral titers, resulted in undetectable virus in the brain, and protected hamsters from almost all SARS-CoV-2-associated weight loss. Highly attenuated COVI-VAC is protective at a single intranasal dose in a relevant in vivo model. This, coupled with its large-scale manufacturing potential, supports its potential use in mass vaccination programs.
Related Papers
No related papers found
Powered by citation graph analysis